Fauci: 'I Have Nothing to Hide'; Title 42 Rule Blocked; Europe's Cancer 'Epidemic'
(MedPage Today) -- Note that some links may require subscriptions. "I have nothing to hide and I can defend everything we've done," said NIAID Director Anthony Fauci, MD, discussing the prospect of House investigations over the pandemic response... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2022 Category: Hematology Source Type: news

AMA Votes to Oppose Punishing Doctors When Necessary Care Results in Fetal Death
(MedPage Today) -- In the wake of the Supreme Court's June decision to overturn Roe v. Wade, the American Medical Association (AMA) House of Delegates Monday voted on a resolution to work against all policies or laws that exact punishment against... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2022 Category: Hematology Source Type: news

Allogeneic CAR T-Cell Therapy Shows Early Promise in Kidney Cancer
(MedPage Today) -- A novel chimeric antigen receptor (CAR) T-cell therapy targeting CD70 showed encouraging activity in a small group of patients with advanced clear cell renal cell carcinoma (ccRCC), with one patient achieving a complete response... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 15, 2022 Category: Hematology Source Type: news

Oral, Hormone-Free Med Reduces Hot Flashes in Breast Cancer Patients
(MedPage Today) -- A novel, non-hormonal oral drug was effective in reducing hot flashes and night sweats in women taking oral adjuvant endocrine therapy after breast cancer, according to results from a phase II study. After 28 days of treatment... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 12, 2022 Category: Hematology Source Type: news

Role of Cytoreductive Nephrectomy Unclear for Dedifferentiated Kidney Cancer
(MedPage Today) -- AUSTIN, Texas -- Cytoreductive nephrectomy improved overall survival (OS) by more than a year for patients with metastatic renal cell carcinoma (mRCC) with sarcomatoid or rhabdoid (S/R) dedifferentiation treated with immunotherapy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 10, 2022 Category: Hematology Source Type: news

More Racial Cancer Disparities; Potential Pharma Bankruptcy; HPV Vax Efficacy
(MedPage Today) -- American Indian and Alaska Native individuals have a substantially higher cancer mortality despite cancer incidence similar to other racial/ethnic groups in the U.S. (American Cancer Society) Non-Hispanic Black patients were... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 10, 2022 Category: Hematology Source Type: news

Immune Stimulator May Enhance Targeted Therapy's Activity in Metastatic RCC
(MedPage Today) -- AUSTIN, Texas -- A dendritic-cell immune primer failed to meet survival endpoints in a randomized trial of high-risk synchronous metastatic renal cell carcinoma (mRCC) but nonetheless showed evidence of activity. The 18-month... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 9, 2022 Category: Hematology Source Type: news

Immunotherapy Doublet Shows Promise for Nonsurgical Control of Small Kidney Cancers
(MedPage Today) -- AUSTIN, Texas -- Unresectable nonmetastatic kidney cancers regressed substantially, but not completely, in response to treatment with nivolumab (Opdivo) and ipilimumab (Yervoy), a small prospective study showed. Six of eight... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 7, 2022 Category: Hematology Source Type: news

Probiotic May Rev Up Response to Immunotherapy in Advanced Kidney Cancer
(MedPage Today) -- AUSTIN, Texas -- Progression-free survival (PFS) in advanced kidney cancer improved dramatically with the addition of a gut-bacteria derivative to immunotherapy, a small randomized trial showed. Median PFS increased from 2... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 7, 2022 Category: Hematology Source Type: news

Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options
(MedPage Today) -- Patients with multiple myeloma who relapse after treatment with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can be salvaged with multiple lines of therapy, a retrospective study suggested... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 4, 2022 Category: Hematology Source Type: news

The High Cost of Cancer; Bone Fracture Risk in Survivors; MRI Gear Shortage
(MedPage Today) -- The annual price of newly launched cancer drugs has increased 53% over the last 5 years, according to a report by U.S. Rep. Katie Porter (D-Calif.). (Reuters) A survey of large employers found that cancer has become the top... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 4, 2022 Category: Hematology Source Type: news

Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma
(MedPage Today) -- Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant increase in the risk of second... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 3, 2022 Category: Hematology Source Type: news

Study: U.S. Chemo Regimen for Ewing Sarcoma Should Be International Standard
(MedPage Today) -- The standard chemotherapy regimen used to treat patients with newly diagnosed Ewing sarcoma in the U.S. was more effective, less toxic, and shorter in duration than the previous standard used in Europe, a phase III randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2022 Category: Hematology Source Type: news

Year in Review: Breast Cancer
(MedPage Today) -- As 2022 draws to a close, breast cancer specialists and their patients can look back on a year that produced a game-changing therapeutic development and several incremental improvements in clinical management. Most observers... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 1, 2022 Category: Hematology Source Type: news

Year in Review: Multiple Myeloma
(MedPage Today) -- Developments in multiple myeloma over the past year were marked by the approvals of a first-in-class drug for relapsed or refractory disease and a second chimeric antigen receptor (CAR) T-cell therapy, as well as some encouraging... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 1, 2022 Category: Hematology Source Type: news